On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of
198,734,444
shares of its common stock, par value $
0.01
per share (the “Kenvue Common Stock”), at an initial public offering of $
22.00
per share for net proceeds of $
4.2
billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $
2.5
billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately
89.6
% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $
1.3
billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023.
On August 23, 2023, Johnson & Johnson completed the disposition of an additional
80.1
% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring
190,955,436
shares of the Company’s common stock in exchange for
1,533,830,450
shares of Kenvue Common Stock. The $
31.4
billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned
9.5
% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $
4.3
billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $
0.4
billion expense through December 31, 2023.
Johnson & Johnson divested net assets of $
11.6
billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $
4.3
billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $
1.2
billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $
21.0
billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $
2.8
billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.
Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters